Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of SYHA1813 versus investigator's choice in recurrent or progressive high-grade meningioma
CTR20244678Phase 2Active
- Sponsor
- Runshi Pharma
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SYHA1813 in meningioma, sponsored by Runshi Pharma. Started Dec 2024; status: active.
02
Drugs
SYHA1813
03
Conditions
meningioma
Beyond the preview
Go deeper on CTR20244678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244678.